- Home
- BLRX vs PMI Comparison
BLRX vs PMI Comparison
Compare BLRX & PMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BLRX | PMI |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | Israel | United States |
| Employees | N/A | 75 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.6M | 14.1M |
| IPO Year | 2010 | N/A |
Fundamental Metrics
Financial Performance| Metric | BLRX | PMI |
|---|---|---|
| Price | $3.06 | $0.15 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | 14.6K | ★ 3.4M |
| Earning Date | 05-26-2026 | 06-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.15 | $0.11 |
| 52 Week High | $4.75 | $13.68 |
Technical Indicators
Market Signals| Indicator | BLRX | PMI |
|---|---|---|
| Relative Strength Index (RSI) | 48.27 | 39.00 |
| Support Level | $3.05 | $0.15 |
| Resistance Level | $3.11 | $0.20 |
| Average True Range (ATR) | 0.22 | 0.02 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 48.30 | 23.32 |
Price Performance
Historical ComparisonAbout BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About PMI Picard Medical Inc.
Picard Medical Inc operates through its wholly owned subsidiary, a medical technology company focused on developing, manufacturing, and commercializing the SynCardia TAH, an implantable total artificial heart system. The company is engaged in designing, manufacturing, producing, supplying, marketing, and selling medical device products, including the SynCardia TAH, which is designed to assume the full function of a failed human heart in patients suffering from advanced heart failure. The SynCardia TAH replaces both the left and right ventricles as well as all four heart valves.